SAN MARINO, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Dr. M. Karen Newell, Ph.D., a lead scientist at biotechnology company Viral Genetics (Pink Sheets: VRAL), will address the 11th Annual SoCalBio Investor and Partnership Conference. Dr. Newell's presentation entitled: "The Impact of Custom Peptides on Chronic Inflammation," will take place mid-morning on Thursday, September 17, 2009. The conference is being held at The Loews Santa Monica Beach Hotel in Santa Monica, California.
Dr. Newell's presentation will include a review of Viral Genetics' previous clinical trials of its HIV/AIDS drug compound VGV-1 and other therapies, as well as the outcome of more recent studies into the mechanism of those therapies. She will cover Viral Genetics' rationale for the current product--custom targeted peptides for conditions characterized by, or requiring in the case of HIV/AIDS---chronic inflammation.
ABOUT VIRAL GENETICS:
Headquartered in San Marino, California, Viral Genetics discovers and develops drug therapies to treat infectious, autoimmune, and immunological deficiency disorders using its thymus nuclear protein compound (TNP). The company has an Exclusive License Agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the company) to license technology developed by M. Karen Newell, Ph.D., that appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. Viral Genetics has formed a wholly owned subsidiary, MetaCytoLytics, Inc, to advance a technology developed by University of Colorado Professor M. Karen Newell called "metabolic disruption technology" (MDT), which focuses on blocking a tumor cell's ability to generate energy from glucose or from fatty acids. Viral Genetics has an option to acquire exclusive rights to the metabolic disruption technology from the University of Vermont and the University of Colorado. Online at http://www.viralgenetics.com/.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of VGV-1 in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.
Contact: Haig Keledjian, 626-334-5310
Viral Genetics
CONTACT: Haig Keledjian of Viral Genetics, +1-626-334-5310
Web Site: http://www.viralgenetics.com/
Company News On-Call: http://www.prnewswire.com/comp/905553 .html
